Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.
about
Oncolytic virus therapy for glioblastoma multiforme: concepts and candidatesVesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerEmerging role of Natural killer cells in oncolytic virotherapyUnderstanding and altering cell tropism of vesicular stomatitis virusCutting Edge: Innate Immune Augmenting Vesicular Stomatitis Virus Expressing Zika Virus Proteins Confers Protective ImmunityCombining Oncolytic Virotherapy with p53 Tumor Suppressor Gene TherapyOncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future PerspectivesExperimental evolution of an oncolytic vesicular stomatitis virus with increased selectivity for p53-deficient cells.Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cellsMurine Tumor Models for Oncolytic Rhabdo-Virotherapy.Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV.Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neckAdvances in stem cells, induced pluripotent stem cells, and engineered cells: delivery vehicles for anti-glioma therapy.Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spreadRecent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.Oncolytic Virotherapy versus Cancer Stem Cells: A Review of Approaches and Mechanisms.Viroimmunotherapy for Colorectal Cancer: Clinical Studies.
P2860
Q27007519-45F79480-B553-401A-9A3A-B3029369BDD2Q27021839-4485A969-D02A-451A-9F62-C4675E1AD644Q27025330-BA83A05B-F52C-475D-847C-E513E89ACA05Q27687067-336BDB95-6A80-4FF5-A520-CF26C5BC96EAQ29365197-DF6488B9-BDE0-441E-980E-63B905972E5CQ33633277-25847897-2A14-412D-979E-DBBD9CFFE22AQ33679505-3D8E6FE6-2706-4743-95DF-B6387D048827Q33882758-58F8F94E-6B94-4FB3-9325-548AD7C35756Q35861186-2867C1E0-282A-43A9-9151-BD5B031E8B36Q35893563-2E71485F-456F-423F-8E91-7068BBAA6B56Q36751597-550EC6D3-F515-4FC1-B2FC-CEC2F0DB36B9Q37123143-25F4005A-FED9-4B34-A933-3C4911C82578Q37373616-7DFC3C2E-DDF1-49A6-997B-4D2EB9615FF4Q37672599-207B5B8D-514B-404B-B485-2681DA6D0AAEQ38227489-C169CF6A-AAE6-45D2-BA17-FB88CDD272CBQ39127778-7CEBE6B5-E699-4EA3-AF27-7D8EEE430F52Q45324769-6ED02AD6-0B31-4A7D-B76B-3D389C96979EQ52688581-6105E5F6-D09C-4605-8325-7E9E91D29527Q52718361-0CDAE46D-F626-469E-88ED-7A8E4BE621F8Q55085114-F2C7311C-5F25-4BB0-B945-C61AE0B97BA4
P2860
Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Vesicular stomatitis virus exp ...... uated, potent oncolytic agent.
@ast
Vesicular stomatitis virus exp ...... uated, potent oncolytic agent.
@en
type
label
Vesicular stomatitis virus exp ...... uated, potent oncolytic agent.
@ast
Vesicular stomatitis virus exp ...... uated, potent oncolytic agent.
@en
prefLabel
Vesicular stomatitis virus exp ...... uated, potent oncolytic agent.
@ast
Vesicular stomatitis virus exp ...... uated, potent oncolytic agent.
@en
P2860
P356
P1433
P1476
Vesicular stomatitis virus exp ...... uated, potent oncolytic agent.
@en
P2093
Glen N Barber
Joshua F Heiber
P2860
P304
10440-10450
P356
10.1128/JVI.05408-11
P407
P577
2011-08-03T00:00:00Z